Skip to main content
SpringerLink
Log in
Book cover

Attempts to Understand Metastasis Formation III pp 189–216Cite as

Immunotherapy of Metastases

  • Chapter

Part of the book series: Current Topics in Microbiology and Immunology ((CT MICROBIOLOGY,volume 213/3))

Abstract

Many aspects of tumor growth and metastasis are dependent on tumor cell-host cell interactions. The capacity of tumor cells to elicit or suppress various host tissue responses seems as important for development of solid tumors as for tumor cell proliferation in different organ microenvironments. The process of tumor angiogenesis, the consequences of which extend far beyond nutrient supply, can serve as an illustrative and important example (Rak et al. 1993). The importance of tumor-host interactions and of signals from the microenvironment for development of cancer metastases was pointed out as early as 1980 (Schirrmacher 1980), but has only recently attracted much attention and been studied at the molecular level (Schirrmacher 1994; Nicolson 1988, 1991; Fidler 1990; Kerbel 1990; Gullino 1991; Heppner 1989). The way in which tumor cells react to signals from the microenvironment is determined by their reception via specific receptors, by the way these signals are transduced, and by the way these transduced signals are translated in the cellular response. Cellular calcium homeostasis is the result and the regulator of many signal transduction pathways and plays a central role of regulation of cell proliferation, invasion, and metastatic potential (Liotta et al. 1991). While the interaction of tumor cells with host endothelial cells and extracellular matrix (Ingber 1991; Ingber and Folkman 1989; Jain 1990) is being discussed by experts contributing to this series of articles, the interaction with cells of the immune system, in particular with antigen-specific immune mechanisms, will be the focus of this review.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Abrams PGA (1995) Antibody-based approaches in cancer therapy: monoclonal antibodies as pharmaceuticals. In: Eccles S (ed) The treatment of cancer: beyond chemotherapy. Documentation of conference in London, 13/14 March 1995

    Google Scholar 

  • Ahlert T, Schirrmacher V (1990) Isolation of a human melanoma adapter Newcastle disease virus mutant with highly selective replication patterns. Cancer Res 50: 5962–5968

    PubMed  CAS  Google Scholar 

  • Ali M, Lemoine N R (1995) Gene therapy for cancer. Abstract at the 8th AEK Symposium, Heidelberg, 29–31 March 1995

    Google Scholar 

  • Altevogt P, Leidig S, Heckl-Oestreicher B (1984) Resistance of metastatic tumor variants to tumor specific cytotoxic T lymphocytes not due to defects in expression of restricting MHC molecules in mice. Cancer Res 44: 5305–5313

    PubMed  CAS  Google Scholar 

  • Alvarez-Diez TM, Polhironis J, Reilly RM (1995) Pre-targeted imaging of LS174T colon cancer xenografts in nude mice with streptavidin (SA)-CC49 monoclonal antibody (Mab) and ln-111-biotin. Proc Am Assoc Cancer Res 36: 616

    Google Scholar 

  • Baskar S, Glimcher L, Nabavi N, Jones RT, Östrand-Rosenberg S (1995) Major histocompatibility complex class ll+B7–1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med 181: 619–629

    PubMed  CAS  Google Scholar 

  • Berd D, Maguire HC, McCue P, Mastrangelo MJ (1990) Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients. J Clin Oncol 8: 1858–1867

    PubMed  CAS  Google Scholar 

  • Berd D, Takami S, Lattime EC, Maguire HC Jr, Hamilton R, Mastrangelo MJ (1995) Assessing the host response to haptenized melanoma vaccine. Proc Am Assoc Cancer Res 36: 677–678

    Google Scholar 

  • Bosslet K, Schirrmacher V (1981) Escape of metastasizing clonal tumor cell variants from tumor-specific cytolytic T lymphocytes. J Exp Med 154: 557–561

    PubMed  CAS  Google Scholar 

  • Bosslet K, Schirrmacher V (1982) High-frequency generation of new immunoresistant tumor variants during metastasis of a cloned murine tumor line (ESb). Int J Cancer 29: 195–202

    PubMed  CAS  Google Scholar 

  • Bosslet K, Czech J, Opper M, Gerken M, Hoffmann D (1995) Tumor selective prodrug activation by b-glucuronidase-mediated catalysis. Abstract at the 8th AEK Symposium, Heidelberg, 29–31 March 1995

    Google Scholar 

  • Cassel WA, Murray DR, Phillips HS (1983) A phase II study on the postsurgical management of stage II malignant melanoma with a Newcastle disease virus oncolysate. Cancer 57: 1302–1312

    Google Scholar 

  • Cassel WA, Weidenheim KM, Campbell WG, Murray DR (1986) Malignant melanoma: inflammatory mononuclear cell infiltrates in cerebral metastases during concurrent therapy with viral oncolysate. Cancer 57: 1302–1312

    PubMed  CAS  Google Scholar 

  • Colombo M, Forni G (1994) Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 15: 48–51

    PubMed  CAS  Google Scholar 

  • Csatary LK, Eckhard S et al. (1993) Attenuated veterinary virus vaccine for the treatment of cancer. Cancer Detec Prevent 17: 619–627

    CAS  Google Scholar 

  • Desai PB (1994) Guest editorial. Understanding the biology of cancer: has this any impact on treatment? J Cancer Res Clin Oncol 120: 193–194

    PubMed  CAS  Google Scholar 

  • Ertel C, Millar NS, Emmerson PT, Schirrmacher V, von Hoegen P (1993) Viral hemagglutinin augments peptide specific cytotoxic T-cell responses. Eur J Immunol 23: 2592–2596

    PubMed  CAS  Google Scholar 

  • Fearon E, Pardoll D, Itaya T, Golumbek P, Levisky H, Simons J, Karasuyama H, Vogelstein B, Frost P (1990) IL-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60: 397–403

    PubMed  CAS  Google Scholar 

  • Ferber I, Scönrich G, Schenkel J, Mellor A, Hämmerling GJ, Arnold B (1994) Levels of peripheral T cell tolerance induced by different doses of tolerogen. Science 263: 674–676

    PubMed  CAS  Google Scholar 

  • Fidler IJ (1990) Critical factors in the biology of human cancer metastasis: 28th G.H.A. Clowes Memorial Award Lecture. Cancer Res 50: 6130–6138

    PubMed  CAS  Google Scholar 

  • Finke JH, Zea AH, Stanley J, Longo DL, Mizoguchi H, Tubbs RR, Wiltrout RH, O’Shea JJ, Kudoh S, Klein E, Bukowski RM, Ochoa AC (1993) Loss of T-cell receptor ζ chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res 53: 5613–5616

    PubMed  CAS  Google Scholar 

  • Gosh P, Sica A, Young HA, Ye J, Franco JL, Wiltrout RH, Longo DL, Rice NR, Komschlies KL (1994) Alterations in NFkB/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy. Cancer Res 54: 2969–2972

    Google Scholar 

  • Gosh SK, White LM, Gosh R, Baukert RB (1990) Vaccination with membrane-associated idiotype provides greater and more prolonged protection of animals from tumor challenge than the soluble form of idiotype. J Immunol 145: 365

    Google Scholar 

  • Gotter S, Kipriyanov S, Haas C, Dübel S, Breitling F, Khazaie K, Schirrmacher V, Little M (1995) A single chain antibody for coupling tumor cells treated with Newcastle disease virus to effector molecules. Tumor Targeting 1: 107–114

    CAS  Google Scholar 

  • Gullino PM (1991) Microenvironment and angiogenic response. Angiogenesis, International Symposium St Gallen, 13–15 March, abstract 136

    Google Scholar 

  • Hanna MG, Pollack VA, Peters LC, Hoover HC (1982) Active specific immunotherapy of established micrometastases with BCG plus tumor cell vaccines. Cancer 49: 659–664

    PubMed  Google Scholar 

  • Hayashi Y, Hoon DSB, Park MS, Terasaki PI, Foshag LJ, Morton DL (1992) Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A. Cell Immunol 139: 411–425

    PubMed  CAS  Google Scholar 

  • Heicappel R, Schirrmacher V, von Hoegen P, Ahlert T, Appelhans B (1986) Prevention of metastatic spread by postoperative immunotherapy with virally modified autologous tumor cells. Int J Cancer 37: 569–577

    Google Scholar 

  • Hellström I, Hellstrom KE (1993) Tumor immunology: an overview. Specific immunotherapy of cancer with vaccines. Ann NY Acad Sci 690: 6–18

    Google Scholar 

  • Heppner GH (1989) Tumor cell societies. J Natl Cancer Inst 81: 648–649

    PubMed  CAS  Google Scholar 

  • Hilleman MR (1993) The promise and the reality of viral vaccines against cancer. In: Bystryn IC, Ferrone S, Livingstone P (eds) Specific immunotherapy of cancer with vaccines

    Google Scholar 

  • Hollinshead S, Stewart THM, Takita H, Dalbow M, Concannon J (1987) Adjuvant specific active lung cancer immunotherapy trials. Cancer 60: 1249–1262

    PubMed  CAS  Google Scholar 

  • Hoover HC, Brandhorst JS, Peters LC, Srudyke MG, Takehita Y, Madariagy I, Muenz LR, Hanna MG Jr (1993) Adjuvant active specific immunotherapy for human colorectal cancer. 6.5 year median follow-up ofa phase III prospective randomized trial. J Clin Oncol 11: 390–399

    PubMed  Google Scholar 

  • Ingber D (1991) Extracellular matrix and cell shape: potential control points for inhibition of angiogenesis. J Cell Biol 47: 236–241

    CAS  Google Scholar 

  • Ingber DE, Folkman J (1989) How does extracellular matrix control capillary morphogenesis? Cell 58: 803–805

    PubMed  CAS  Google Scholar 

  • Jain RK (1990) Vascular and interstitial barriers to delivery of therapeutic agents in tumors. Cancer Metastasis Rev 9: 253–266

    PubMed  CAS  Google Scholar 

  • Janeway CA (1989) A primitive immune system. Nature 341: 108

    PubMed  CAS  Google Scholar 

  • June CH, Gluesone JA, Nadler LM, Thompson CB (1994) The B7 and CD28 receptor families. Immunol Today 15: 321–331

    PubMed  CAS  Google Scholar 

  • Jurianz K, Haas C, Hubbe M, Enel C, Brunner G, Alterogt P, Schirrmacher V, von Hoegen P (1995) Adhesive function of Newcastle disease virus hemagglutinin in tumor-host interaction. Int J Oncol 7: 539–545

    CAS  Google Scholar 

  • Kaido T, Maury C, Schirrmacher V, Gresser I (1994) Successful immunotherapy of the highly metastatic murine ESb lymphoma with sensitized CD8+ T-cells and lfn-α/β. Int J Cancer 57: 538–543

    PubMed  CAS  Google Scholar 

  • Kaminski M, Auerbach R (1988) Tumor cells are protected from NK-cell-mediated lysis by adhesion to endothelial cells. Int J Cancer 41: 847–849

    CAS  Google Scholar 

  • Keller ET, Burkholder JK, Shi F, Pugh TD, McCabe D, Malter JS, MacEwen EG, Yang N, Ershler WB (1995) Particle-mediated cytokine gene transfer into canine oral mucosa and epidermis in vivo. Proc Am Assoc Cancer Res 36: 418

    Google Scholar 

  • Kenney S, Pagano JS (1994) Editorial. Viruses as oncolytic agents: a new age for therapeutic viruses? J Natl Cancer Inst 86: 185

    Google Scholar 

  • Kerbel RS (1990) Growth dominance of the metastatic cancer cell: cellular and molecular aspects. Adv Cancer Res 55: 87–132

    PubMed  CAS  Google Scholar 

  • Khazaie K, Prifti S, Beckhove P, Griesbach A, Rüssel S, Collins M, Schirrmacher V (1994) Persistence of dormant tumor-cells in the bone marrow of tumor-cell-vaccinated mice correlates with long term immunological protection. Proc Natl Acad Sci USA 91: 7430–7434

    PubMed  CAS  Google Scholar 

  • Kotera Y, Fontenot JD, Pecher G, Methgar RS, Finn OJ (1994) Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res 54: 2856–2860

    PubMed  CAS  Google Scholar 

  • Krüger A, Schirrmacher V, von Hoegen P (1994a) Scattered micrometastasis visualized at the single cell level: detection and re-isolation of lac Z labeled metastasizing lymhoma cells. Int J Cancer 58: 275–284

    PubMed  Google Scholar 

  • Krüger A, Umansky V, Rocha M, Hacker JJ, Schirrmacher V, von Hoegen P (1994b) Pattern and load of spontaneous liver metastasis dependent on host immune status studied with lacZ transduced lymphoma. Blood 84(9): 3166–3174

    PubMed  Google Scholar 

  • Kumar L (1994) Leukemia: management of relapse after allogeneic bone marrow transplantation. J Clin Oncol 12: 1710–1717

    PubMed  CAS  Google Scholar 

  • Lehner B, Schlag P, Liebrich W, Schirrmacher V (1991) Postoperative active specific immunization in curatively respected colorectal cancer patients with virus-modified autologous tumor cell vaccine. Cancer Immunol Immunother 32: 173–178

    Google Scholar 

  • Liebrich W, Schlag P, Manasterski M, Lehner B, Stöhr M, Möller P, Schirrmacher V (1991) In vitro and clinical characterization of a Newcastle-disease-virus-modified autologous tumor cell vaccine for treatment of colorectal cancer patients. Eur J Cancer 27: 703–710

    PubMed  CAS  Google Scholar 

  • Lindemann F, Schlinok G, Dwischedl P, Witte J, Riethmüller G (1992) Prognostic significance of micrometastatic tumor cells in bone marrow of colorectal cancer patients. Lancet 340: 685–689

    PubMed  CAS  Google Scholar 

  • Liotta LA, Steeg PS, Stetler-Stevenson WG (1991) Cancer metastasis and angiogenesis: an imbalance of positive and nagative regulation. Cell 64: 327–336

    PubMed  CAS  Google Scholar 

  • Lorence RM, Reichard KW, Katubig BB et al. (1994) Complete regression of human neuroblastoma xenografts in athymic mice after local Newcastle disease virus therapy. J Natl Cancer Inst 86: 1228–1233

    PubMed  CAS  Google Scholar 

  • Mitchell MS, Hare W, Kempf RA (1990) Active specific immunotherapy for melanoma. J Clin Oncol 8: 856–869

    PubMed  CAS  Google Scholar 

  • Mizoguchi H, O’Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC (1992) Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 258: 1795–1797

    PubMed  CAS  Google Scholar 

  • Mukherji B, Chakraborty NG, Ymasaki S, Okino T, Sporn J, Kurtzman S, Yamase H, Ergin MT (1995) In vivo immunogenicity of mage-1 nonapeptide-pulsed autologous macrophages in melanoma patients. Proc Am Assoc Cancer Res 36: 675–676

    Google Scholar 

  • Nakagomi H, Petersson M, Magnusson I, Juhlin C, Matsuda M, Mellstedt H, Taupin J-L, Vivierr E, Anderson P, Kiessling R (1993) Decreased expression of the signal-transducting ζ chains in tumor-infiltrating T cells and NK cells of patients with colorectal carcinoma. Cancer Res 53: 5610–5612

    PubMed  CAS  Google Scholar 

  • Nicolson GL (1988) Organ specificity of tumor metastasis: role of preferential adhesion invasion and growth of malignant cells at specific secondary sites. Cancer Metastasis Rev 7: 143–188

    PubMed  CAS  Google Scholar 

  • Nicolson GL (1991) Gene expression, cellular diversification and tumor progression to the metastatic phenotype. Bioessays 13: 337–342

    PubMed  CAS  Google Scholar 

  • Östrand-Rosenberg S (1994) Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Curr Opin Immunol 6: 722–727

    PubMed  Google Scholar 

  • Oliver RTD (1995) A new look at tumor immunology and immunotherapy. Biotherapy 9 (2): 119

    Google Scholar 

  • Osband ME, Lavin PT, Babayan RK, Graham S, Lamm DL, Parker B, Sawaczyck I, Ross S, Krane RJ (1990) Effect of autolymphocyte therapy on survival and quality of life in patients with metastatic renal cell carcinoma. Lancet 335: 994–998

    PubMed  CAS  Google Scholar 

  • Paget S (1889) Lancet i: 571–573

    Google Scholar 

  • Pekarek LA, Starr BA, Toledano A, Schreiber H (1995) inhibition of tumor growth by elimination of granulocytes. J Exp Med 181: 435–440

    PubMed  CAS  Google Scholar 

  • Plaksin D, Progador A, Vadai E, Feldman M, Schirrmacher V, Eisenbach L (1994) Effective anti-metastatic melanoma vaccination with tumor cells transfected with MHC genes and/or infected with Newcastle disease virus (NDV). Int J Cancer 59: 796–801

    PubMed  CAS  Google Scholar 

  • Pomer S, Schirrmacher V, Thiele R, Löhrke H, Staehler G (1995) Tumor response and 4 year survival data of patients with advanced renal cell carcinoma treated with autologous tumor vaccine and subcutaneous rr-IL-2 and IFN-alpha 2b. Int J Oncol (in press)

    Google Scholar 

  • Rak JW, Hegmann EJ, Kerbel RS (1993) The role of angiogenesis in tumor progression and metastasis. Adv Mol Cell Biol 7: 205–251

    Google Scholar 

  • Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trümper L, Hartmann F, Diehl V, van Lier R, Pfreundschuh M (1994) Cure of xenografted human tumors by bispecifics and human T cells. Science 264: 833

    PubMed  CAS  Google Scholar 

  • Renschier M, Dower WJ, Levy R (1995) Development of peptide therapy for lymphoma; random peptide libraries on phage for the identification of B cell receptor ligands. Proc Am Assoc Cancer Res 366: 669–670

    Google Scholar 

  • Riethmüller G, Schneider-Gädicke E, Schlinok G et al. (1994) Randomized trial of monoclonal antibody for adjuvant therapy of resected Duke’s C colorectal carcinoma. Lancet 343: 1177–1183

    PubMed  Google Scholar 

  • Rocha M, Krüger A, Van Rooijen N, Schirrmacher V, Umansky V (1995a) Liver endothelial cells participate in T cell dependent host resistance to lymphoma metastasis by production of nitric oxide in vivo. Int J Cancer 63: 405–411

    PubMed  CAS  Google Scholar 

  • Rocha M, Krüger A, Umansky V, von Hoegen P, Maor D, Schirrmacher V (1995b) Dynamic expression-changes in vivo of adhesion and costimulatory molecules determine load and pattern of lymphoma liver metastases (submitted)

    Google Scholar 

  • Rosenberg SA, Lotze MT, Yang JC, Topalian SL, Chang AE, Schwartzentruber DJ, Aebersold P, Leitman S, Linehan WM, Seipp CA, White DE, Steinberg SM (1993) Prospective randomized trial of high-dose interleukin-2 alone or in conjuction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 85: 622–632

    PubMed  CAS  Google Scholar 

  • Schirrmacher V (1980) Commentary. Shifts in tumor cell phenotypes induced by signals from the microenvironment: relevance for the immunobiology of cancer metastasis. Immunobiology 157:89–98

    PubMed  CAS  Google Scholar 

  • Schirrmacher V (1985) Cancer metastasis: experimental approaches, theoretical concepts and impacts for treatment strategies. Adv Cancer Res 43: 1–73

    PubMed  CAS  Google Scholar 

  • Schirrmacher V (1992) Immunity and metastasis: in situ activation of protective T cells by virus modified cancer vaccines. Cancer Surv 13: 129–154

    PubMed  CAS  Google Scholar 

  • Schirrmacher V (1993) Active specific immunotherapy (ASI) - a new modality of cancer treatment involving the patients own immune system. Onkologie 16: 290–296

    Google Scholar 

  • Schirrmacher V (1994) Tumor-Wirts Interaktionen und Signal-Austausch bei der Metastasierung. In: Macher E, Kolde G, Bröcker EB (eds) Jahrbuch der Dermatologie. Tumoren und Haut. Biermann, Zülpich, pp 53–65

    Google Scholar 

  • Schirrmacher V (1995) Augmentation of protective immunotherapy against metastatic ESb lymphoma cells by combining immune cell transfer with host irradiation, antigen restimulation and/or anti-TNF-a antibody treatment. Int J Oncol 6: 17–25

    CAS  Google Scholar 

  • Schirrmacher V, Barz D (1986) Characterization of cellular and extracellular plasmamembrane vesicles from a low metastatic lymphoma (Eb) and its high metastatic variant (ESb): inhibitory capacity in cell-cell interaction systems. Biochim Biophys Acta 860: 236–242

    PubMed  CAS  Google Scholar 

  • Schirrmacher V, Griesbach A (1994) Adoptive transfer of protective immunity against a high metastatic tumor cell variant by small numbers of tumor specific in situ activated peritoneal effector T-cells. Int J Oncol 5: 141–151

    PubMed  CAS  Google Scholar 

  • Schirrmacher V, von Hoegen P (1993) Importance of tumor cell membrane integrity and viability for CTL activation by cancer vaccines. Vaccine Res 2: 183–196

    Google Scholar 

  • Schirrmacher V, Zangemeister-Wittke U (1994) γ-lrradiation suppresses T cell mediated protective immunity against a metastatic tumor in the afferent phase of the immune response but enhances it in the efferent phase if given before immune cell transfer. Int J Oncol 4: 335–346

    PubMed  CAS  Google Scholar 

  • Schirrmacher V, Landolfo S, Zawatzky R, Kirchner H (1981) Immunogenetic studies on the resistance of mice to highly metastatic DBA/2 tumor cell variants II. Influence of minor histocompatibility antigens on tumor resistance, gamma interferon induction and cytotoxic response. Invasion Metastasis 1: 175–194

    PubMed  CAS  Google Scholar 

  • Schirrmacher V, Fogel M, Rußmann E, Bosslet K, Altevogt P, Beck L (1982) Antigenic variation in cancer metastasis. Immune escape versus immune control. Cancer Metastasis Rev 1: 241–274

    PubMed  CAS  Google Scholar 

  • Schirrmacher V, Ahlert T, Heicappell R, Appelhans B, von Hoegen P (1986) Successful application of non-oncogenic viruses for anti-metastatic cancer immunotherapy. Cancer Rev 1: 241–272

    Google Scholar 

  • Schirrmacher V, von Hoegen P, Schlag P, Liebrich W, Lehner B, Schumacher K, Ahlert T, Bastert G (1989) Active specific immunotherapy with autologous tumor cell vaccines modified by Newcastle disease virus: experimental and clinical studies. In: Schirrmacher V, Schwartz-Albiez R (eds) Cancer metastasis. Springer, Berlin Heidelberg New York, pp157–170

    Google Scholar 

  • Schirrmacher V, von Hoegen P, Griesbach A, Zangemeister-Wittke U (1991) Specific eradication of micrometastases by transfer of tumor immune T-cells from MHC congenic mice. Cancer Immunol Immunother 32: 373–381

    PubMed  CAS  Google Scholar 

  • Schirrmacher V, Schild HJ, Gückel B, von Hoegen P (1992) Tumor specific CTL response requiring interactions of four different cell types and dual recognition of MHC class I and class II restricted tumor antigens. Immunol Cell Biol 71: 311–326

    Google Scholar 

  • Schirrmacher V, Schlag P, Liebrich W, Patel B, Stoeck M (1993) Specific immunotherapy of colorectal carcinoma with Newcastle-disease-virus-modified autologous tumor cells prepared from resected liver metastases. Ann NY Acad Sci 690: 364–366

    PubMed  CAS  Google Scholar 

  • Schirrmacher V, Beckhove P, Krüger A, Rocha M, Umansky V, Fichtner KP, Hull WE, Zangemeister-Wittke U, Griesbach A, Jurianz K, von Hoegen P (1995) Effective immune rejection of advanced metastasized cancer. Int J Oncol 6: 505–521

    PubMed  CAS  Google Scholar 

  • Schlag P, Manasterski M, Gerneth T, Hohenberger P, Dueck M, Herfarth C, Liebrich W, Schirrmacher V (1992) Active specific immunotherapy with NDV modified autologous tumor cells following liver metastases resection in colorectal cancer. Cancer Immunol Immunother 35: 325–330

    PubMed  CAS  Google Scholar 

  • Schmid U, Schirrmacher V, Monburg F, Matzku S (1993) Preferential antibody targeting to small lymphoma metastases in the absence of the primary tumor. Eur J Cancer 29A: 217–225

    PubMed  CAS  Google Scholar 

  • Schönrich G, Kalinke U, Momburg F, Malissen M, Schmitt-Verhulst AM, Malissen B, Hämmerling GJ, Arnold B (1991) Downregulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell 65: 293–304

    PubMed  Google Scholar 

  • Schreiber H (1993) Tumor immunology. In: Paul NE (ed) Fundamental immunology, 3rd edn. Raven, New York. 32: 1143–1178

    Google Scholar 

  • Schwartz RH (1990) A cell culture model for T lymphocyte clonal anergy. Science 258: 1349–1356

    Google Scholar 

  • Seung S, Urban JL, Schreiber H (1993) A tumor escape variant that has lost one major histocompatibility complex class I restriction element induces specific CD8+ T cells to an antigen that no longer serves as a target. J Exp Med 178: 933–940

    PubMed  CAS  Google Scholar 

  • Shrivastava PK, Udono H (1994) Heat-shock protein-peptide complexes in cancer immunotherapy. Curr Opin Immunol 6/5: 728–732

    Google Scholar 

  • Slavin S, Ackerstein A, Weiss L, Nagler A, Reuven O, Naparstek E (1992) Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest 10: 221–227

    PubMed  CAS  Google Scholar 

  • Springer CJ (1995) Antibody-directed enzyme prodrug therapy (ADEPT) as an approach to cancer treatment. In: Eccles S (ed) The treatment of cancer: beyond chemotherapy. Documentation of conference in London, 13/14 March 1995

    Google Scholar 

  • Suzuki Y, Suzuki T, Matsunaga M, Matsumoto M (1985) Gangliosides as paramyxovirus receptor. J Biochem 97: 1189–1199

    PubMed  CAS  Google Scholar 

  • Tallberg T, Tykkä H, Mahlberg K, Haltturen P, Lehtonen T, Kalima T, Sarna S (1985) Active-specific immunotherapy with supportive measures in the treatment of palliatively nephrectomized renal adenocarcinoma. A thrirteen year follow-up study. Eur Urol 811 (4): 233–234

    Google Scholar 

  • Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA (1990) A highly immunogenic tumor transfected with a murine transforming growth factor type ß1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 87: 1486–1490

    PubMed  CAS  Google Scholar 

  • Turk JL, Parker D (1982) Effect of cyclosphosphamide on immunologial control mechanisms. Immunol Rev 65: 99–113

    PubMed  CAS  Google Scholar 

  • Umansky V, Rocha M, Krüger A, von Hoegen P, Schirrmacher V (1995) In situ activated macrophages are involved in host resistance to lymphoma metastasis by production of nitricoxide. Int J Oncol 7: 33–40

    PubMed  CAS  Google Scholar 

  • Vaage J (1985) Natural and induced resistance to metastasis from mouse mammary carcinomas. In: Torisu M, Yoshida T (eds) Basic mechanisms and clinical treatment of tumor metastasis. Academic, New York, pp 163–189

    Google Scholar 

  • Vitetta ES (1995) Monoclonal antibodies as carriers of toxins and as agonists in the therapy of lymphoma. Richard and Hinda Rosenthal Foundation Award Lecture. Proc Am Assoc Cancer Res 36: 646

    Google Scholar 

  • Von Hoegen P, Altevogt P, Schirrmacher V (1987) New antigens presented on tumor cells can cause immune rejection without influencing the frequency of tumor-specific cytolytic T cells. Cell Immunol 109: 338–348

    Google Scholar 

  • Von Hoegen P, Weber E, Schirrmacher V (1988) Modification of tumor cells by a low dose of Newcastle disease virus; augmentation of the tumor-specific T cell response in the absence of an anti-viral response. Eur J Immunology 18: 1159–1166

    Google Scholar 

  • Von Hoegen P, Zawatzky R, Schirrmacher V (1990) Modification of tumor cells by a low dose of Newcastle disease virus III. Potentiation of tumor specific cytolytic T cell activity via induction of interferon alfa, beta. Cell Immunol 126: 80–90

    Google Scholar 

  • Wunderlich M, Schiessel R, Rainer H, Rauhs R, Kovat E, Schemper M, Dittrich C, Mielesche M, Sedlacek HH (1985) Effect of adjuvant chemo- or immunotherapy on the prognosis of colorectal cancer operated for cure. Br J Surg 72 [Suppl]: 107–110

    Google Scholar 

  • Ye QW, Mokyr MB (1984) Cyclophosphamide-induced appearance of immunopotentiating T cells in the spleens of mice bearing a large MOPC-315 tumor. Cancer Res 44: 3873–3879

    PubMed  CAS  Google Scholar 

  • Zangemeister-Wittke U, Schirrmacher V (1991) Transfer of long-lasting tumor immunity by immune T cells from MHC congenic mice: migration, survival and tumor protectivity of cytotoxic donor cells. Biotherapy 3: 319–329

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cellular Immunology (0710), German Cancer Research Center, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany

    V. Schirrmacher, V. Umansky & M. Rocha

Authors
  1. V. Schirrmacher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V. Umansky
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Rocha
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Basel Institute for Immunology, Grenzacherstraße 487, CH-4005, Basel, Switzerland

    Ursula Günthert Ph.D., P.D.

  2. Virchow Klinikum, Chirurgische Abteilung, Robert-Rössle-Klinik, Max-Delbrück-Centrum Berlin, Lindenberger Weg 80, D-13122, Berlin, Germany

    Peter M. Schlag M.D.

  3. Max-Delbrück-Centrum für Molekulare Medizin, Robert-Rössle-Straße 10, D-13122, Berlin, Germany

    Walter Birchmeier Ph.D.

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Schirrmacher, V., Umansky, V., Rocha, M. (1996). Immunotherapy of Metastases. In: Günthert, U., Schlag, P.M., Birchmeier, W. (eds) Attempts to Understand Metastasis Formation III. Current Topics in Microbiology and Immunology, vol 213/3. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-80071-9_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-80071-9_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-80073-3

  • Online ISBN: 978-3-642-80071-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation